Enoxaparin may be safe for patients with cancer, brain metastases
the ONA take:
According to a new study published online in the journal Blood, researchers have found that patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin, a type of low molecular weight heparin anticoagulant, without increased risk of intracranial hemorrhage.
For the study, researchers sought to assess the risk of intracranial hemorrhage, a dangerous form of bleeding in the head, associated with the administration of therapeutic doses of enoxaparin.
Researchers identified 239 patients with cancer and brain metastases. Of those, 104 received therapeutic enoxaparin and 189 were their matched controls that did not receive blood-thinning treatment.
Results showed that there were no differences in the cumulative incidence of intracranial hemorrhage at 1 year in the enoxaparin and control cohorts.
Researchers found that patients with melanoma or renal cell carcinoma had a fourfold higher risk of intracranial hemorrhage than those with lung cancer, but administration of enoxaparin did not affect that risk. The study also showed that overall survival was similar in both groups.
Patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|